“Gene editing and cell therapy, they’re going to be entrenched modalities, much like small molecules and antibodies are today, that will fundamentally reshape healthcare.” says Devyn Smith. Devyn Smith, CEO of Arbor Biotechnologies and Chairman of the Alliance for Regenerative
Stephen Sheehan of Alkermes shares their new governance framework for high-performing CDMO partnerships. As Director of External Development & Manufacturing at Alkermes, Stephen Sheehan brings over a decade of experience in pharmaceutical development. Having transitioned from small to large molecules,
“For us, it’s not a transaction. It really is a partnership,” says Nikki Whitfield, CEO of Upperton Pharma Solutions. Nikki Whitfield brings over three decades of pharmaceutical development experience to her role as CEO of Upperton Pharma Solutions. A chemist
Hanns-Christian Mahler, Chief Enablement Officer at ten23 health, is redefining leadership in pharmaceutical manufacturing: “I believe collaboration at the workplace should be primarily based on trust and motivation, not on typical carrot and stick command and control models.” Founded in
John Childers, Director of Business Development for Wacker Biotech’s North American operations, emphasises the importance of early CDMO partnerships: “Working with an experienced CDMO partner can really help you stay on track for budget and schedule. Think long term –
“The pharma industry has a looming revenue gap. We’ve estimated $300 billion of pharma revenue at risk from loss of exclusivity over the next five years,” warns Jeff Holder, Partner at L.E.K. Consulting. Adam Siebert and Jeff Holder are partners
David Caron, Senior Vice-President of CMC, AL102 at Immunome, shares why choosing the right CDMO partner can make or break a biotech’s development timeline: “For biotechs, the main business challenge is to do right the first time. To do this,
Dr. Avencia Sánchez-Mejías is CEO and co-founder of Integra Therapeutics, a Barcelona-based biotech company developing next-generation gene-editing tools. With a background in molecular biology and clinical genetics, she brings over 15 years of experience in genetic therapy research across Europe,
“The reality is, we have a lot of CDMOs that don’t really know what they’re getting into” says Herman Bozenhardt Herman Bozenhardt, a pharmaceutical manufacturing consultant with decades of experience in facility design and operations, brings a wealth of knowledge
GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2030. However, their rapid rise raises important questions about resource allocation in pharmaceutical development and manufacturing, as well
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups Sign up for our weekly newsletter
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
